Breaking news in Targeted Oncology online today - A New Drug Application (NDA) for Ripretinib (DCC-2618) was submitted to FDA for treatment of GIST, by Deciphera.
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing email@example.com with the subject line SUBSCRIBE LRG SCIENCE.
Esta presentación cuenta la historia de los medicamentos para GIST, de cómo llagamos a donde hoy estamos, y como miramos hacia donde vamos en el futuro. Entrega información de cada medicamento que ha sido [...]
The 16th annual Night to Fight Cancer (NTFC) took place on October 24th, 2019 at the Midtown Loft and Terrace in New York City. This annual event benefits The Life Raft Group’s research programs. LRG Board President Jerry Cudzil co-hosted the event with colleague, Matthew Knopman.
Pete Knox's presentation on current and emerging medications for GIST.
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Jodi Lang shares her story.
The LRG held a GIST Mentor training day in our offices in Wayne, NJ, in October 2019. The gallery includes photos of the new GIST Mentors, LRG staff. One of the training days was on Halloween so some of the staff dressed up. These photos were taken by David Josephy of Life Raft Group Canada.
Participación de los pacientes en el “Tour de abogacía por la participación de los pacientes en la toma de decisiones en políticas públicas de salud.”
Sara Rothschild, LRG VP Program Services, met with Othon Iliopoulos, MD, Harvard Medical School/Massachusetts General Hospital Cancer Center, to discuss how to understand and make progress in SDH-related diseases.
Sara Rothschild, VP Programs and Services at the LRG, attended an executive education program at the Harvard Business School which brought together leaders from the health care, scientific, technological, and business communities to speed progress and drive cures.